NMN may refer to: National Monuments Council Nicotinamide mononucleotide Nigerian Merchant Navy Numbered musical notation "No middle name", sometimes used in legal documents for people with no middle name NMN, the National Rail station code for New Mills Newtown railway station, Derbyshire, England

What are the risks of NMN?

NMN has an excellent acute safety profile in human clinical trials conducted to date. Multiple phase I and II trials in healthy adults (250–2,000 mg/day for 12 weeks) have found no significant adverse effects, with NMN well tolerated and measurably increasing NAD+ levels in blood. Safety profile fro

How long does NMN last?

The total duration of NMN via oral is 12 hours to 24 hours. Onset typically occurs within 15 minutes to 1 hour.

NMN — SubstanceWiki

NMN may refer to:

National Monuments Council
Nicotinamide mononucleotide
Nigerian Merchant Navy
Numbered musical notation
"No middle name", sometimes used in legal documents for people with no middle name
NMN, the National Rail station code for New Mills Newtown railway station, Derbyshire, England
nmn, the ISO 639 code for the Taa language

Topics referred to by the same term

This disambiguation page lists articles associated with the title NMN. If an internal link incorrectly led you here, you may wish to change the link to point directly to the intended article.

Retrieved from "https://en.wikipedia.org/w/index.php?title=NMN&oldid=1178088606" Category: - Disambiguation pages

Hidden categories: - Short description is different from Wikidata

All article disambiguation pages
All disambiguation pages
This page was last edited on 1 October 2023, at 14:36(UTC).
Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Legal & safety contacts
Code of Conduct
Developers
Statistics
Cookie statement
Mobile view

NMN

4 languages

Add topic

Pharmacology

Nicotinamide mononucleotide (NMN) is a nucleotide composed of nicotinamide (vitamin B3 amide form) and ribose-5-phosphate. It is the immediate precursor to NAD+ in the NAD+ salvage pathway: NMN + ATP → NAD+ + PPi, catalyzed by NMN adenylyltransferases (NMNAT1/2/3 — nuclear, cytoplasmic/Golgi, and mitochondrial isoforms, respectively). This spatial distribution of NMNATs means NMN must reach multiple cellular compartments to restore NAD+ in each.

Cellular entry: NMN enters cells through the specific transporter Slc12a8 (identified in 2019 by Grozio et al., though since debated), and also via extracellular conversion to nicotinamide riboside (NR) by CD73 (5'-ectonucleotidase), which then enters cells and is rephosphorylated to NMN by NR kinases (NRK1/2).

NAD+ restoration: NAD+ levels decline by approximately 50% between youth and middle age in multiple tissues, attributed to increased NAD+ consumption (by sirtuins, PARPs — both upregulated by DNA damage and metabolic stress) and decreased salvage pathway efficiency. NMN supplementation restores NAD+ levels in aged tissues in multiple species, with effects in blood, skeletal muscle, liver, kidney, and brain.

Downstream targets: NAD+ restored by NMN fuels: sirtuins (SIRT1-7; SIRT1 and SIRT3 for metabolic regulation; SIRT6 for DNA repair and telomere integrity; SIRT2 for microtubule stability), PARPs (particularly PARP1 for base excision repair and strand break repair), and CD38 (major NADase; CD38 expression increases with age and inflammation, significantly contributing to NAD+ decline; CD38 inhibitors including apigenin and quercetin are popular "NAD+ stack" co-supplements).

Brain-specific effects: NMN crosses the blood-brain barrier and restores NAD+ in aging neurons. It enhances neurovascular coupling (the mechanism by which neural activity increases local blood flow), reduces neuroinflammation via sirtuin activation, protects against cognitive decline in aging mouse models, and has shown effects on amyloid pathology in Alzheimer's mouse models.

Full	Unknown
Half	Unknown
Zero	Unknown

NMN

Quick Dosage

Dosage

Oral

Duration

Oral

Pharmacology

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Tolerance

Legal Status

Tips (3)

References (4)

Frequently Asked Questions